Palisade Bio's phase 2b ASCENTRA-UC trial for ulcerative colitis has begun dosing, with 12-week topline results expected in Q4 2027. I rate PALI stock as Buy.

Caldera Therapeutics, Inc. (“Caldera”), a privately held clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting IL-23p19 and TL1A for the treatment of inflammatory ...

Investor’s Business Daily cut its suggested exposure to 0% to 20%. The indexes are weak, but money is moving into the stocks ...

Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the ...

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not ...

Kaken stock is in focus after a reported collaboration with Numab on the inflammatory bowel disease candidate ND081. The deal ...

10/13/2026 04:44 PM ET Alissa Coram and Ken Shreve walk through Tuesday's market action with a discussion of key stocks to watch in Stock ...

Not many stocks have been able to withstand the deluge of selling pressure in the stock market in October. The Nasdaq ...

Looking for the best green investments? IBD's 50 Most Sustainable Companies combine high sustainability scores and superior stock ratings.